Latest Breaking News On - Keytruda biosimilar - Page 1 : vimarsana.com

The trial will compared the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and pembrolizumab for metastatic non-squamous non-small cell lung cancer.

Ilsun hongGallaghera samsung bioepisSamsung bioepisKeytruda biosimilarKeytruda pembrolizumabSamsung bioepis co ltdProduct evaluation team leader of samsung bioepisProduct evaluation team leaderEuropean union sourcedUnited states sourcedImmunogenicity betweenBioepis initiates phaseProposed biosimilarProposed keytruda